Plexium is a technology-first drug development company. We develop ‘molecular glues’ that alter E3-ligase substrate recognition; inducing, inhibiting or modulating degradation of proteins for therapeutic benefit. Our deep engineering background allows us to screen for molecular-glue degraders in massively high throughput cell-based assays utilizing DNA-encoded libraries.
We also have the ability to capture transcriptional and proteomic responses of cells to very large chemical-libraries. This ability allows us to generate Perturbation | Response databases for hundreds of millions of compounds across various cell types. We intend to use the combination of phenotypic and target-specific screens to identify first-in-class therapeutics for challenging indications.